1 published article · Updated continuously
6 trials tracked for Keratitis: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 12 citations.
Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical evidence for keratitis management includes the use of Acthar 1, ciclosporin at a dose of 1mg/mL 2, and T4020 4. Additionally, specific formulations such as B+L Biotrue MPS and B+L PureVision have been evaluated in clinical settings 3.
The combination of Loteprednol and tobramycin demonstrated significant improvements in the Signs and Symptoms Composite Score from baseline to Day 15. In the PP population, scores improved by -11.63 and -12.41 respectively, while the ITT population showed improvements of -11.64 and -11.98 5. Significant improvement was also noted in the PP population at Day 8 with scores of -9.20 and -10.21 5.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
